These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22883288)

  • 1. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juvenile myasthenia gravis: three case reports and a literature review.
    Gadient P; Bolton J; Puri V
    J Child Neurol; 2009 May; 24(5):584-90. PubMed ID: 19406758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
    Lin PT; Martin BA; Weinacker AB; So YT
    Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.
    Baek WS; Bashey A; Sheean GL
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):771. PubMed ID: 17575026
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppressive therapies in myasthenia gravis.
    Sanders DB; Evoli A
    Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory generalized myasthenia gravis with rituximab.
    Lebrun C; Bourg V; Tieulie N; Thomas P
    Eur J Neurol; 2009 Feb; 16(2):246-50. PubMed ID: 19146644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Actual aspects of myasthenia gravis treatment].
    Czapliński A; Radziwiłł AJ; Steck AJ
    Pol Merkur Lekarski; 2003 Mar; 14(81):256-60. PubMed ID: 12914109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis.
    Hilkevich O; Drory VE; Chapman J; Korczyn AD
    Clin Neuropharmacol; 2001; 24(3):173-6. PubMed ID: 11391130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia gravis and visceral lupus erythematosus].
    Truniger B
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1847-51. PubMed ID: 394318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
    Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
    Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.